AOD-9604 in Black / African Ancestry Patients: Safety Profile Differences

AOD-9604 (also written as HGH fragment 176-191, or by the brand name used by some compounders, "AOD9604") is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone, with an added N-terminal tyrosine. It is not a growth hormone secretagogue and is not the same molecule as full-length recombinant HGH. No randomized trial of AOD-9604 has ever reported ancestry-stratified results, so there is no direct evidence that its safety profile differs in Black or African ancestry patients. What exists instead is a set of well-established, population-level differences in renal disease risk, cardiometabolic baseline, and enzyme deficiency prevalence that plausibly change the risk-benefit calculation for this specific peptide, even though no one has tested that hypothesis directly.

This is the core answer: AOD-9604 has never been studied in an ancestry-stratified trial, it is not FDA-approved for any indication, and it is used off-label through compounding pharmacies. Because Black patients in the United States carry, on average, higher documented rates of hypertension, chronic kidney disease, and G6PD deficiency, and because AOD-9604 is renally cleared, a clinician extrapolating population-level risk data (not peptide-specific trial data) would reasonably apply closer renal, hematologic, and cardiometabolic monitoring in this population until dedicated pharmacokinetic studies exist.

Evidence boundary: what is established, what is plausible, what is not known

Established: AOD-9604 is not FDA-approved as a drug. It received Generally Recognized as Safe (GRAS) status from the FDA in 2014, but only as a food ingredient, not as an injectable therapeutic (FDA GRAS Substances database). Its clinical development ended after a Phase IIb trial failed to separate from placebo on the primary weight-loss endpoint; the sponsor did not pursue further approval. Separately, it is well established in U.S. public health data that Black adults carry higher population rates of hypertension and chronic kidney disease than White adults, and that glucose-6-phosphate dehydrogenase (G6PD) deficiency is more common in people of African ancestry than in the general U.S. population (CDC kidney disease data, WHO G6PD testing guidance).

Plausible but unproven: That these baseline population differences translate into a materially different safety margin specifically for AOD-9604. This is a reasonable clinical inference, not a demonstrated finding, because the peptide itself has never been tested in a population with these risk factors under controlled conditions.

Not established: Any ancestry-specific pharmacokinetic parameter for AOD-9604 (half-life, clearance, effective dose range), any documented case of AOD-9604 triggering a hemolytic event in a G6PD-deficient patient, and any ancestry-stratified dosing guideline. These gaps should be stated plainly to patients and not filled in with confident-sounding numbers.

A note on the exact figures sometimes cited for these disparities (specific percentages for hypertension prevalence, CKD prevalence ratios, or G6PD deficiency rates by subgroup): these numbers move over time and by dataset, and the specific primary sources for several of them could not be independently verified for this draft. Clinicians should confirm current figures directly from the CDC, AHA, ADA, or WHO source pages linked in this article rather than relying on a single remembered statistic.

How AOD-9604 is thought to work

AOD-9604 was designed to isolate the lipolytic (fat-mobilizing) region of the growth hormone molecule while removing the growth-promoting and diabetogenic activity associated with the intact GH receptor pathway. Preclinical work in obese mice reported fat mass reduction with the fragment without the glucose intolerance seen with full-length GH; a formal check of the exact study parameters (dose, duration, and species-to-human translation) is recommended before repeating specific figures from that work, since animal dosing and duration do not reliably predict human outcomes. The proposed mechanism is that AOD-9604 acts through a receptor or pathway distinct from the canonical GH receptor, though that pathway has not been molecularly characterized in humans. Because it has not been characterized, there is no way to know whether it is expressed, or expressed at different levels, across ancestral populations.

Why ancestry-specific data would matter here, if it existed

Three population-level facts are relevant to how a prescriber should think about AOD-9604 in Black patients, independent of any peptide-specific data:

Cardiorenal baseline risk. Hypertension and chronic kidney disease are both more prevalent in Black adults than in White adults in U.S. population data (CDC, AHA Heart Disease and Stroke Statistics). AOD-9604 is presumed to be cleared through renal peptidase activity. A patient with reduced kidney function, for any reason, may experience prolonged exposure to any renally cleared peptide. This is a general pharmacology principle, not something demonstrated for AOD-9604 specifically, but it is the reason renal function should be checked before starting and monitored during treatment in anyone with risk factors for kidney disease, regardless of ancestry.

G6PD deficiency prevalence. G6PD deficiency is more common in people of African, Mediterranean, and Southeast Asian ancestry than in the general population, and it is the most common human enzymopathy worldwide. WHO guidance recommends G6PD testing before prescribing drugs with uncertain oxidative potential in populations where deficiency is more common (WHO). AOD-9604 has not been studied for hemolytic risk in G6PD-deficient patients. There is no reported case of AOD-9604 triggering hemolysis. The absence of a reported case is not the same as evidence of safety, because the drug has not been used in large, monitored populations with G6PD testing built in. Screening before initiation is a low-cost, low-risk precaution rather than a response to a documented signal.

Diabetes prevalence. Type 2 diabetes is more prevalent among non-Hispanic Black adults than non-Hispanic White adults in ADA reporting (ADA Standards of Care). Preclinical work suggested AOD-9604 does not raise glucose or insulin in animal models, but there is no human glucose-monitoring data for this peptide stratified by ancestry or by baseline glycemic status. Patients with pre-diabetes or diabetes starting AOD-9604 should still have fasting glucose or HbA1c monitored, because the animal finding does not settle the human question.

Pharmacogenomics: mostly a gap, not a finding

No pharmacogenomic guideline body (PharmGKB, CPIC, or equivalent) has issued dosing or safety guidance for AOD-9604. The peptide is presumed to be degraded by standard peptidases rather than metabolized through cytochrome P450 enzymes, which would make CYP2D6 or CYP2C19 polymorphism frequency differences across populations largely irrelevant. That presumption is reasonable given the peptide's structure, but it has not been confirmed in a formal human pharmacokinetic study. Claims about growth hormone receptor polymorphism frequency differing by ancestry, or about baseline GH pulse amplitude differing by ancestry, appear in the endocrinology literature, but the specific figures require verification against the primary papers before being used to guide an individual dosing decision. Until that verification happens, the honest clinical statement is: baseline GH-axis biology may differ by ancestry in ways relevant to a GH-fragment peptide, and this has not been tested for AOD-9604 specifically.

Renal function: the highest-priority monitoring domain

Because AOD-9604 is believed to be renally cleared, the reader-facing decision that matters most is whether renal function should be checked before starting, and how often afterward.

APOL1 risk variants, which are more common in individuals with recent West African ancestry, are associated with a substantially higher lifetime risk of certain kidney diseases, including focal segmental glomerulosclerosis and hypertensive nephropathy. This is a genuinely established finding in nephrology (the original description is a well-known 2010 genetics study), but the exact relative-risk figures and allele frequencies should be confirmed with a nephrology reference rather than repeated from memory, since these numbers are precise enough to be misquoted easily.

Separately, the CKD-EPI creatinine equation was revised in 2021 to remove a race coefficient that had been shown to overestimate glomerular filtration rate in Black patients under the older formula. This change has been adopted broadly across U.S. laboratories and is endorsed by kidney and endocrine professional societies. A prescriber ordering renal labs for a patient starting AOD-9604 should confirm the lab is using the current, race-neutral equation, since an inflated eGFR could understate a patient's true renal clearance and lead to over-dosing of any renally cleared compound.

For a patient with an eGFR under 60 mL/min/1.73 m², there is no validated AOD-9604 dose adjustment. The conservative options are to avoid the peptide in moderate-to-severe CKD or to reduce dosing frequency and monitor renal function more closely, neither of which is evidence-based for this specific peptide, only for renally cleared compounds generally.

A practical monitoring approach

The following is a reasonable, conservative monitoring structure built from general pharmacology principles and known population risk factors, not from an AOD-9604-specific trial protocol, since none exists.

Before starting: basic metabolic panel with creatinine and eGFR (race-neutral equation), fasting lipid panel, fasting glucose or HbA1c, blood pressure, and a G6PD screen if not already documented, particularly in male patients of African ancestry.

Around 4 weeks: renal function recheck, fasting glucose, blood pressure, and a symptom check for any signs of hemolysis (fatigue, jaundice, dark urine) if G6PD status is unknown or deficient.

Around 12 weeks: full metabolic panel, lipid panel, HbA1c, blood pressure, and a clinical decision point on whether to continue, adjust, or stop.

Ongoing: metabolic and lipid panels, blood pressure, and clinical response review at a frequency the prescriber sets based on the individual's baseline risk, not a fixed ancestry-based rule.

Patients who develop unexplained fatigue, jaundice, dark urine, flank pain, significant blood pressure change, or rapid unexplained weight change while on AOD-9604 should stop the peptide and seek prompt medical evaluation rather than waiting for a scheduled follow-up.

Population-specific evidence and transferability map

This table separates what has actually been studied about AOD-9604 from what is extrapolated from general population health data, and flags where specialist input is warranted before prescribing.

Dosing: no validated ancestry-specific adjustment exists

Compounding pharmacy protocols for AOD-9604 commonly use 250-500 mcg subcutaneously once daily in a fasting state, or a weight-based approach of roughly 3-5 mcg/kg/day in some practices. Neither approach has been validated in a controlled trial, and no dose-finding study has stratified results by ancestry or body composition. A conservative approach is to start at the lower end of whatever range a prescriber uses, titrate based on tolerability over several weeks, and rely on standardized follow-up labs rather than a fixed formula, since there is no dose-response curve established for this compound in any population, let alone one stratified by ancestry.

What this article cannot tell you

No amount of extrapolation from population health statistics substitutes for a peptide-specific trial. The gaps that matter most: AOD-9604 has never completed a Phase III trial in any population, its full receptor pathway has not been molecularly characterized, and compounded formulations of the peptide are not standardized in purity or excipients across pharmacies, which introduces variability into any safety observation independent of the patient's ancestry. A patient or clinician looking for a definitive, ancestry-specific answer on AOD-9604 safety will not find one in the current literature. What can be offered honestly is a monitoring approach built from known, well-documented population health differences, applied conservatively until better data exist.